Shoreline Dialysis Center is a medicare approved dialysis facility center in Branford, Connecticut and it has 16 dialysis stations. It is located in New Haven county at 34 East Industrial Road, Branford, CT, 06405. You can reach out to the office of Shoreline Dialysis Center at (203) 315-8113. This dialysis clinic is managed and/or owned by Fresenius Medical Care. Shoreline Dialysis Center has the following ownership type - Profit. It was first certified by medicare in August, 2000. The medicare id for this facility is 072522 and it accepts patients under medicare ESRD program.
| Name | Shoreline Dialysis Center |
|---|---|
| Location | 34 East Industrial Road, Branford, Connecticut |
| No. of Dialysis Stations | 16 |
| Medicare ID | 072522 |
| Managed By | Fresenius Medical Care |
| Ownership Type | Profit |
| Late Shifts | No |
| 34 East Industrial Road, Branford, Connecticut, 06405 | |
| (203) 315-8113 | |
News Archive
Establishing a more stringent ozone standard in the U.S. would significantly reduce ozone-related premature mortality and morbidity, according to a new study published online July 18 in the journal Environmental Health Perspectives.
Medecins Sans Frontieres, the Drugs for Neglected Diseases initiative, and the Mount Sinai School of Medicine this week are hosting a conference in New York, titled "Lives in the Balance: Delivering Medical Innovations for Neglected Patients and Populations," the Philadelphia Inquirer reports.
In the first large scale, multiethnic study of its kind, researchers at UCLA have confirmed the role played by three particular molecules known as cytokines as a cause of Type 2 diabetes, and further, have identified these molecules as early biological markers that may be used to more accurately predict future incidences of diabetes among apparently healthy individuals.
An Oregon Health & Science University Cancer Institute research laboratory has developed a novel mouse model designed specifically to study the often devastating head and neck squamous cell cancers.
Azaya Therapeutics, Inc. announced today that the Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for its lead product "ATI-1123," a novel and improved formulation of Taxotere® (docetaxel), a leading chemotherapy drug with worldwide annual sales of over $2.8 billion.
› Verified 3 days ago
| NPI Number | 1457360166 |
| Organization Name | Shoreline Dialysis Center |
| Doing Business As | St. Raphael Dialysis Center Partnership |
| Address | 34 E Industrial Rd Branford, Connecticut, 06405 |
| Phone Number | (203) 315-5031 |
News Archive
Establishing a more stringent ozone standard in the U.S. would significantly reduce ozone-related premature mortality and morbidity, according to a new study published online July 18 in the journal Environmental Health Perspectives.
Medecins Sans Frontieres, the Drugs for Neglected Diseases initiative, and the Mount Sinai School of Medicine this week are hosting a conference in New York, titled "Lives in the Balance: Delivering Medical Innovations for Neglected Patients and Populations," the Philadelphia Inquirer reports.
In the first large scale, multiethnic study of its kind, researchers at UCLA have confirmed the role played by three particular molecules known as cytokines as a cause of Type 2 diabetes, and further, have identified these molecules as early biological markers that may be used to more accurately predict future incidences of diabetes among apparently healthy individuals.
An Oregon Health & Science University Cancer Institute research laboratory has developed a novel mouse model designed specifically to study the often devastating head and neck squamous cell cancers.
Azaya Therapeutics, Inc. announced today that the Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for its lead product "ATI-1123," a novel and improved formulation of Taxotere® (docetaxel), a leading chemotherapy drug with worldwide annual sales of over $2.8 billion.
› Verified 3 days ago
| Dialysis patients with Hemoglobin data | 40 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 13 |
News Archive
Establishing a more stringent ozone standard in the U.S. would significantly reduce ozone-related premature mortality and morbidity, according to a new study published online July 18 in the journal Environmental Health Perspectives.
Medecins Sans Frontieres, the Drugs for Neglected Diseases initiative, and the Mount Sinai School of Medicine this week are hosting a conference in New York, titled "Lives in the Balance: Delivering Medical Innovations for Neglected Patients and Populations," the Philadelphia Inquirer reports.
In the first large scale, multiethnic study of its kind, researchers at UCLA have confirmed the role played by three particular molecules known as cytokines as a cause of Type 2 diabetes, and further, have identified these molecules as early biological markers that may be used to more accurately predict future incidences of diabetes among apparently healthy individuals.
An Oregon Health & Science University Cancer Institute research laboratory has developed a novel mouse model designed specifically to study the often devastating head and neck squamous cell cancers.
Azaya Therapeutics, Inc. announced today that the Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for its lead product "ATI-1123," a novel and improved formulation of Taxotere® (docetaxel), a leading chemotherapy drug with worldwide annual sales of over $2.8 billion.
› Verified 3 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 67 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 594 |
| Percentage of adult patients getting regular hemodialysis at the center | 100 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
Establishing a more stringent ozone standard in the U.S. would significantly reduce ozone-related premature mortality and morbidity, according to a new study published online July 18 in the journal Environmental Health Perspectives.
Medecins Sans Frontieres, the Drugs for Neglected Diseases initiative, and the Mount Sinai School of Medicine this week are hosting a conference in New York, titled "Lives in the Balance: Delivering Medical Innovations for Neglected Patients and Populations," the Philadelphia Inquirer reports.
In the first large scale, multiethnic study of its kind, researchers at UCLA have confirmed the role played by three particular molecules known as cytokines as a cause of Type 2 diabetes, and further, have identified these molecules as early biological markers that may be used to more accurately predict future incidences of diabetes among apparently healthy individuals.
An Oregon Health & Science University Cancer Institute research laboratory has developed a novel mouse model designed specifically to study the often devastating head and neck squamous cell cancers.
Azaya Therapeutics, Inc. announced today that the Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for its lead product "ATI-1123," a novel and improved formulation of Taxotere® (docetaxel), a leading chemotherapy drug with worldwide annual sales of over $2.8 billion.
› Verified 3 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Shoreline Dialysis Center with elevated calcium levels.
| Patients with hypercalcemia | 75 |
| Hypercalcemia patient months | 654 |
| Patients with Serumphosphor | 78 |
| Patients with Serumphosphor less than 3.5 mg/dL | 13 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 33 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 33 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 15 |
| Patients with Serumphosphor greater than 7 mg/dL | 6 |
News Archive
Establishing a more stringent ozone standard in the U.S. would significantly reduce ozone-related premature mortality and morbidity, according to a new study published online July 18 in the journal Environmental Health Perspectives.
Medecins Sans Frontieres, the Drugs for Neglected Diseases initiative, and the Mount Sinai School of Medicine this week are hosting a conference in New York, titled "Lives in the Balance: Delivering Medical Innovations for Neglected Patients and Populations," the Philadelphia Inquirer reports.
In the first large scale, multiethnic study of its kind, researchers at UCLA have confirmed the role played by three particular molecules known as cytokines as a cause of Type 2 diabetes, and further, have identified these molecules as early biological markers that may be used to more accurately predict future incidences of diabetes among apparently healthy individuals.
An Oregon Health & Science University Cancer Institute research laboratory has developed a novel mouse model designed specifically to study the often devastating head and neck squamous cell cancers.
Azaya Therapeutics, Inc. announced today that the Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for its lead product "ATI-1123," a novel and improved formulation of Taxotere® (docetaxel), a leading chemotherapy drug with worldwide annual sales of over $2.8 billion.
› Verified 3 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 68 |
| Patient months included in arterial venous fistula and catheter summaries | 531 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 60 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 29 |
News Archive
Establishing a more stringent ozone standard in the U.S. would significantly reduce ozone-related premature mortality and morbidity, according to a new study published online July 18 in the journal Environmental Health Perspectives.
Medecins Sans Frontieres, the Drugs for Neglected Diseases initiative, and the Mount Sinai School of Medicine this week are hosting a conference in New York, titled "Lives in the Balance: Delivering Medical Innovations for Neglected Patients and Populations," the Philadelphia Inquirer reports.
In the first large scale, multiethnic study of its kind, researchers at UCLA have confirmed the role played by three particular molecules known as cytokines as a cause of Type 2 diabetes, and further, have identified these molecules as early biological markers that may be used to more accurately predict future incidences of diabetes among apparently healthy individuals.
An Oregon Health & Science University Cancer Institute research laboratory has developed a novel mouse model designed specifically to study the often devastating head and neck squamous cell cancers.
Azaya Therapeutics, Inc. announced today that the Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for its lead product "ATI-1123," a novel and improved formulation of Taxotere® (docetaxel), a leading chemotherapy drug with worldwide annual sales of over $2.8 billion.
› Verified 3 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 69 |
| Hospitalization Rate in facility | 169.3 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 287.5 |
| Hospitalization Rate: Lower Confidence Limit | 102.6 |
News Archive
Establishing a more stringent ozone standard in the U.S. would significantly reduce ozone-related premature mortality and morbidity, according to a new study published online July 18 in the journal Environmental Health Perspectives.
Medecins Sans Frontieres, the Drugs for Neglected Diseases initiative, and the Mount Sinai School of Medicine this week are hosting a conference in New York, titled "Lives in the Balance: Delivering Medical Innovations for Neglected Patients and Populations," the Philadelphia Inquirer reports.
In the first large scale, multiethnic study of its kind, researchers at UCLA have confirmed the role played by three particular molecules known as cytokines as a cause of Type 2 diabetes, and further, have identified these molecules as early biological markers that may be used to more accurately predict future incidences of diabetes among apparently healthy individuals.
An Oregon Health & Science University Cancer Institute research laboratory has developed a novel mouse model designed specifically to study the often devastating head and neck squamous cell cancers.
Azaya Therapeutics, Inc. announced today that the Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for its lead product "ATI-1123," a novel and improved formulation of Taxotere® (docetaxel), a leading chemotherapy drug with worldwide annual sales of over $2.8 billion.
› Verified 3 days ago
The rate of readmission show you whether patients who were being treated regularly at Shoreline Dialysis Center were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 26.2 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 39.7 |
| Readmission Rate: Lower Confidence Limit | 15.2 |
News Archive
Establishing a more stringent ozone standard in the U.S. would significantly reduce ozone-related premature mortality and morbidity, according to a new study published online July 18 in the journal Environmental Health Perspectives.
Medecins Sans Frontieres, the Drugs for Neglected Diseases initiative, and the Mount Sinai School of Medicine this week are hosting a conference in New York, titled "Lives in the Balance: Delivering Medical Innovations for Neglected Patients and Populations," the Philadelphia Inquirer reports.
In the first large scale, multiethnic study of its kind, researchers at UCLA have confirmed the role played by three particular molecules known as cytokines as a cause of Type 2 diabetes, and further, have identified these molecules as early biological markers that may be used to more accurately predict future incidences of diabetes among apparently healthy individuals.
An Oregon Health & Science University Cancer Institute research laboratory has developed a novel mouse model designed specifically to study the often devastating head and neck squamous cell cancers.
Azaya Therapeutics, Inc. announced today that the Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for its lead product "ATI-1123," a novel and improved formulation of Taxotere® (docetaxel), a leading chemotherapy drug with worldwide annual sales of over $2.8 billion.
› Verified 3 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Shoreline Dialysis Center get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | .76 (As Expected) |
| SIR: Upper Confidence Limit | 1.69 |
| SIR: Lower Confidence Limit | .28 |
News Archive
Establishing a more stringent ozone standard in the U.S. would significantly reduce ozone-related premature mortality and morbidity, according to a new study published online July 18 in the journal Environmental Health Perspectives.
Medecins Sans Frontieres, the Drugs for Neglected Diseases initiative, and the Mount Sinai School of Medicine this week are hosting a conference in New York, titled "Lives in the Balance: Delivering Medical Innovations for Neglected Patients and Populations," the Philadelphia Inquirer reports.
In the first large scale, multiethnic study of its kind, researchers at UCLA have confirmed the role played by three particular molecules known as cytokines as a cause of Type 2 diabetes, and further, have identified these molecules as early biological markers that may be used to more accurately predict future incidences of diabetes among apparently healthy individuals.
An Oregon Health & Science University Cancer Institute research laboratory has developed a novel mouse model designed specifically to study the often devastating head and neck squamous cell cancers.
Azaya Therapeutics, Inc. announced today that the Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for its lead product "ATI-1123," a novel and improved formulation of Taxotere® (docetaxel), a leading chemotherapy drug with worldwide annual sales of over $2.8 billion.
› Verified 3 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Shoreline Dialysis Center's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 60 |
| Transfusion Rate in facility | 31.8 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 79 |
| Transfusion Rate: Lower Confidence Limit | 14.3 |
News Archive
Establishing a more stringent ozone standard in the U.S. would significantly reduce ozone-related premature mortality and morbidity, according to a new study published online July 18 in the journal Environmental Health Perspectives.
Medecins Sans Frontieres, the Drugs for Neglected Diseases initiative, and the Mount Sinai School of Medicine this week are hosting a conference in New York, titled "Lives in the Balance: Delivering Medical Innovations for Neglected Patients and Populations," the Philadelphia Inquirer reports.
In the first large scale, multiethnic study of its kind, researchers at UCLA have confirmed the role played by three particular molecules known as cytokines as a cause of Type 2 diabetes, and further, have identified these molecules as early biological markers that may be used to more accurately predict future incidences of diabetes among apparently healthy individuals.
An Oregon Health & Science University Cancer Institute research laboratory has developed a novel mouse model designed specifically to study the often devastating head and neck squamous cell cancers.
Azaya Therapeutics, Inc. announced today that the Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for its lead product "ATI-1123," a novel and improved formulation of Taxotere® (docetaxel), a leading chemotherapy drug with worldwide annual sales of over $2.8 billion.
› Verified 3 days ago
The rate of mortality show you whether patients who were being treated regularly at Shoreline Dialysis Center lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 346 |
| Mortality Rate in facility | 13.6 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 17.5 |
| Mortality Rate: Lower Confidence Limit | 10.4 |
News Archive
Establishing a more stringent ozone standard in the U.S. would significantly reduce ozone-related premature mortality and morbidity, according to a new study published online July 18 in the journal Environmental Health Perspectives.
Medecins Sans Frontieres, the Drugs for Neglected Diseases initiative, and the Mount Sinai School of Medicine this week are hosting a conference in New York, titled "Lives in the Balance: Delivering Medical Innovations for Neglected Patients and Populations," the Philadelphia Inquirer reports.
In the first large scale, multiethnic study of its kind, researchers at UCLA have confirmed the role played by three particular molecules known as cytokines as a cause of Type 2 diabetes, and further, have identified these molecules as early biological markers that may be used to more accurately predict future incidences of diabetes among apparently healthy individuals.
An Oregon Health & Science University Cancer Institute research laboratory has developed a novel mouse model designed specifically to study the often devastating head and neck squamous cell cancers.
Azaya Therapeutics, Inc. announced today that the Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for its lead product "ATI-1123," a novel and improved formulation of Taxotere® (docetaxel), a leading chemotherapy drug with worldwide annual sales of over $2.8 billion.
› Verified 3 days ago
Shoreline Dialysis Center Location: 34 East Industrial Road, Branford, Connecticut, 06405 Phone: (203) 315-8113 |
U.S.Renal Care Branford Dialysis Location: 322 East Main Street, Branford, Connecticut, 06405 Phone: (203) 483-0710 |
News Archive
Establishing a more stringent ozone standard in the U.S. would significantly reduce ozone-related premature mortality and morbidity, according to a new study published online July 18 in the journal Environmental Health Perspectives.
Medecins Sans Frontieres, the Drugs for Neglected Diseases initiative, and the Mount Sinai School of Medicine this week are hosting a conference in New York, titled "Lives in the Balance: Delivering Medical Innovations for Neglected Patients and Populations," the Philadelphia Inquirer reports.
In the first large scale, multiethnic study of its kind, researchers at UCLA have confirmed the role played by three particular molecules known as cytokines as a cause of Type 2 diabetes, and further, have identified these molecules as early biological markers that may be used to more accurately predict future incidences of diabetes among apparently healthy individuals.
An Oregon Health & Science University Cancer Institute research laboratory has developed a novel mouse model designed specifically to study the often devastating head and neck squamous cell cancers.
Azaya Therapeutics, Inc. announced today that the Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for its lead product "ATI-1123," a novel and improved formulation of Taxotere® (docetaxel), a leading chemotherapy drug with worldwide annual sales of over $2.8 billion.
› Verified 3 days ago